Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05683808 · ClinicalTrials.gov registry record · Phase 2

Venous Thromboembolism Prevention in Outpatients With Glioma

A Phase 2 study of Glioblastoma and Venous Thromboembolism, sponsored by University of Vermont Medical Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT05683808: Recruiting Phase 2 study of Glioblastoma and Venous Thromboembolism, sponsored by University of Vermont Medical Center.

NCT05683808 is a Phase 2 study of Glioblastoma and Venous Thromboembolism that is actively recruiting participants, run by University of Vermont Medical Center. The registered enrollment target is 40 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05683808, a Phase 2 study of Glioblastoma and Venous Thromboembolism, is actively recruiting participants, sponsored by University of Vermont Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

Primary Outcome

CTCAE 5 reporting of grade 2 non-Central Nervous System (CNS) hemorrhage or grade 2 new CNS hemorrhage.

Conditions Studied

Glioblastoma Venous Thromboembolism Astrocytoma

Interventions

  • DRUG Apixaban

Study Locations (1)

Vermont

  • University of Vermont Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-01-16
Est. Completion 2027-06-30
Phase Phase 2
University of Vermont Medical Center

27 total trials

What NCT05683808 shows while recruiting

NCT05683808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (63% lower).

The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.

NCT05683808 reports a single indexed study location in Vermont.

Frequently Asked Questions

What is clinical trial NCT05683808 about?

NCT05683808 is a clinical study titled "Venous Thromboembolism Prevention in Outpatients With Glioma". This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

What is the current status of trial NCT05683808?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-01-16. Estimated completion is 2027-06-30.

What conditions does trial NCT05683808 study?

This clinical trial studies the following conditions: Glioblastoma, Venous Thromboembolism, Astrocytoma.

What interventions are being tested in trial NCT05683808?

The interventions under investigation include: Apixaban (DRUG).

Who is sponsoring clinical trial NCT05683808?

This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05683808 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05683808's enrollment target sits among peer trials

40 103rd of 199 higher than 94 of 199 other Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05683808

Source: ClinicalTrials.gov NCT05683808, the US trial registry maintained by the National Library of Medicine. NCT05683808 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.